We use cookies on this site to enable your digital experience. By continuing to use this site, you are agreeing to our cookie policy. close

Glaxo Agrees To $65M Settlement In Antitrust Suit Over Paxil Patent Gaming: Report

Law360 (February 3, 2005, 12:00 AM EST) -- In a deal that closely resembles similar settlements for arthritis drug Relafen and prescription antibiotic Augmentin, GlaxoSmithKline has reportedly agreed to pay $65 million to settle a class action antitrust suit brought by consumers who accused the U.K. drug maker of filing "sham" patent lawsuits to delay generic competition for antidepressant Paxil.

In the proposed settlement, which is awaiting final approval by U.S. District Judge John R. Padova, Glaxo admitted no liability and maintains its position that its litigation efforts were not designed to cause any...
To view the full article, register now.
Law360 Pro Say Podcast
Check out Law360's new podcast, Pro Say, which offers a weekly recap of both the biggest stories and hidden gems from the world of law.